Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Other

Stephen David Harrison

David B Ring

Angelica Medina-Selby

Doris Guenzi Coit

John Andrew Hall

Maria Calderon-Cacia

Ziyang Zhong

Steve H Nguyen

Eric Y Fang

John M Nuss

Savithri Ramurthy

Keith Bruce Pfister

Allan S Wagman

Kirk William Johnson

Rustum S Boyce

Lynn Seely

Dane A Goff

Paul A Renhowe

Xiaohui A Zhou

Peter G Schultz

Manoj C Desai

Lewis T Williams

Sharadha Subramanian

Barry Haskell Levine

Andrew Malcolm Bray

Sean P Brown

Cynthia Shafer

Sabina Pecchi

Christopher McBride

Paul Andrew Barsanti

W Michael Kavanaugh

Simon C Ng

Zhi-Jie Ni

Timothy D Machajewski

Marion Wiesmann

Elisa Jazan

William R McCrea

Carla C Heise

Kelly Wayman

Dennis G Fry

Anke Klippel

Ute Hoch

Johanna M Jansen

Dirksen Bussiere

Christine Taylor Brew

Darren W Davis

Joel B Silver

Licen Xu

A combination tandem cutting ax head and adz is disclosed that is adapted to firefighting. The ax may include a front end that is divided between a concave portion and a flat section. The concavity creates edges for cutting through surfaces, while the flat section functions to hinder the ax head from becoming wedged in the material. An adz may be provided in which the fulcrum is raised above the head and located between the handle and the adz edge, which increases the lever arm.

Firefighter's ax

Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.

Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents

The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&#x3b1; and GSK3&#x3b2; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

GSK3 polypeptides

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes. 

Benzimidazole quinolinones and uses thereof

New pyridine-based compounds of Formula I, compositions, and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3-mediated disorders in vivo are provided. The methods, compounds, and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer. 

Inhibitors of glycogen synthase kinase 3

Inhibitors of glycogen synthase 3 kinase

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

Polynucleotide constructs encoding growth factor independent catalytically active membrane targeted PI 3-kinase mutants useful for therapeutic and research purposes are described. In addition, a method for using the polynucleotide constructs to screen for inhibitors of PI 3-kinase, a method for making 3&prime; phosphorylated inositol phospholipids, methods of reducing cell death after trauma, and methods of overcoming insulin resistance are described.

PI 3-kinase fusion mutants and uses thereof

The invention is generally directed to compositions and methods for affecting signal transduction using the casein kinase I (CKI) gene or gene product. The invention is more specifically directed to affecting the Wnt signal pathway using the CKI gene or gene product. The invention is particularly directed to using the CKI gene or gene product to treat and diagnose cancer, particularly breast and colon cancer. CKI&egr; is the preferred species. The field of the invention is compositions and methods for modulating signal transduction using the (CKI) gene or gene products and variants thereof. The invention is more specifically directed to modulating the Wnt signal pathway using the CKI gene or gene product. The invention is particularly directed to using the CKI gene or gene product to treat and diagnose disorders mediated by the Wnt signal pathway, especially hyperproliferative disorders, particularly breast and colon cancer.

Compositions and methods of diagnosis and treatment using casein kinase I

Growing community of inventors

Albany, CA, United States of America

Stephen David Harrison